Caribou Biosciences, Inc. (CRBU): Price and Financial Metrics


Caribou Biosciences, Inc. (CRBU): $8.28

-0.36 (-4.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRBU to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CRBU Stock Price Chart Interactive Chart >

Price chart for CRBU

CRBU Price/Volume Stats

Current price $8.28 52-week high $32.65
Prev. close $8.64 52-week low $6.41
Day low $7.96 Volume 1,254,600
Day high $9.06 Avg. volume 642,967
50-day MA $8.48 Dividend yield N/A
200-day MA $16.05 Market Cap 502.64M

Caribou Biosciences, Inc. (CRBU) Company Bio


Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.


CRBU Latest News Stream


Event/Time News Detail
Loading, please wait...

CRBU Latest Social Stream


Loading social stream, please wait...

View Full CRBU Social Stream

Latest CRBU News From Around the Web

Below are the latest news stories about Caribou Biosciences Inc that investors may wish to consider to help them evaluate CRBU as an investment opportunity.

10 Biotech Stocks to Sell Now According to Cathie Wood

In this article, we discuss 10 biotech stocks to sell now according to Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to 5 Biotech Stocks to Sell Now According to Cathie Wood. The mass sell-off of stocks in the high growth sector has not been very kind to […]

Yahoo | February 22, 2022

Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17th, at 2:20 pm ET. A live webcast of the discussion will be accessible via Caribou’s website on the Events page. The ar

Yahoo | February 7, 2022

Is Caribou Biosciences, Inc. (NASDAQ:CRBU) Popular Amongst Insiders?

Every investor in Caribou Biosciences, Inc. ( NASDAQ:CRBU ) should be aware of the most powerful shareholder groups...

Yahoo | January 21, 2022

Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer

Dr. Rizvi brings significant experience in oncology cell therapy developmentBERKELEY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Syed Rizvi, M.D., to the newly created position of chief medical officer. Dr. Rizvi has more than two decades of experience in all stages of drug development, from clinical strategy and execution through regulatory submis

Yahoo | January 18, 2022

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 9:45 am ET. A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived

Yahoo | January 4, 2022

Read More 'CRBU' Stories Here

CRBU Price Returns

1-mo 6.29%
3-mo N/A
6-mo -52.95%
1-year N/A
3-year N/A
5-year N/A
YTD -45.13%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4353 seconds.